位点和大小控制的PEGylation调节了自身免疫性疾病模型中的双功能的生物界面和免疫调节功能
Su Jeong Song1, Andrea Lucia Villela Nava1, Jin Xie1
1Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, Kansas 66047, United States.
ACS applied materials & interfaces
|January 15, 2026
概括
使用PEGylation的生物界面工程优化了用于治疗自身免疫性疾病的双功能抑制剂 (BPIs). 这种策略增强了免疫调节,对新型免疫疗法有很大的前景.
科学领域:
- 免疫学 免疫学 免疫学
- 生物技术是生物技术.
- 聚合物化学 聚合物化学
背景情况:
- 自身免疫性疾病源于T细胞失调,目前广泛的免疫抑制剂会引起副作用.
- 抗原特异性疗法,如双功能抑制剂 (BPIs),旨在阻止T细胞共刺激,但面临降解和疗效问题.
研究的目的:
- 开发一种生物界面工程策略,使用受控的PEGylation来增强BPIs的免疫调节特性和体内疗效.
- 优化PEGylation (位置和大小) 以改善细胞相互作用和免疫调节.
主要方法:
- 具有不同PEG链长度 (1-10kDa) 和位的BPI的位点和大小控制的PEG化.
- 在实验室中评估树突细胞吸收,共刺激标记物表达和调控性免疫表型诱导.
- 在实验性自身免疫脑膜炎 (EAE) 鼠标模型中的体内评估.
主要成果:
- 最佳配置,间隔器结合的5kDa PEG-BPI (S-5k),平衡的生物活性,分散和免疫调节.
- S-5k显示增强了树突细胞的吸收和降低了共刺激标记物的调节,诱导了调节性免疫表型.
- S-5k治疗显著改善了EAE症状,并增加了免疫抑制细胞 (Tregs,M2巨细胞).
结论:
- 基化作为细胞接口的空间调节器,不仅仅是药理动力学.
- 以PEGylation为指导的生物界面控制是免疫治疗中聚合物-联体的可行设计原则.
- 这种方法有可能开发出有效的转化免疫疗法来治疗自身免疫性疾病.
相关概念视频
Covalently Linked Protein Regulators
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein.
These groups modify specific amino acids in a protein.
Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).


